Targets › CFB
5 programs from 5 companies in 18 trials: 10 Phase 3, 6 Phase 2, 2 Phase 1; Hematology, Ophthalmology, Genitourinary; next expected readout Dec 2026.
Precursor of the catalytic component of the C3 and C5 convertase complexes of the alternative pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. The alternative complement pathway acts as an amplification loop that enhances other complement pathways (classical, lectin and GZMK) by promoting formation…. (UniProt, P00751)
Open in Phaseline: the race on CFB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Iptacopan Complement factor B inhibitor | CFB | Phase 3 | C3G; Generalized Myasthenia Gravis; Paroxysmal Nocturnal Hemoglobinuria; Atypical Hemolytic Uremic Syndrome … | Dec 2026 |
| Suzhou Sanegene Bio | SGB-9768 Factor B (CFB) inhibitor | CFB | Phase 2 | IgA Nephropathy (IgAN) | Dec 2026 |
| Nanjing Chia-tai Tianqing Pharmaceutical | NTQ5082 Factor B (CFB) inhibitor | CFB | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | Jul 2027 |
| Kriya Therapeutics | VV-14295 (KRIYA-825) Adeno-associated virus (AAV) vector delivering a soluble fms-like tyrosine kinase-1 (sFlt- | CFB | Phase 1 | Geographic Atrophy Secondary to Age-related Macular Degeneration | Dec 2027 |
| Regeneron Pharmaceuticals | ALN-CFB small interfering RNA (siRNA) targeting Complement Factor B | CFB | Phase 1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Nov 2029 |
Paroxysmal Nocturnal Hemoglobinuria (PNH) (2) Paroxysmal Nocturnal Hemoglobinuria (2) Atypical Hemolytic Uremic Syndrome (2) Geographic Atrophy Secondary to Age-related Macular Degeneration (1) C3G (1) Generalized Myasthenia Gravis (1) IC-MPGN (1) Primary Immunoglobulin A Nephropathy (IgAN) (1) Primary IgA Nephropathy (1) C3 Glomerulopathy (1) Lupus Nephritis (1) Age-Related Macular Degeneration (1)
small molecule (4), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.